Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 20;43(1):380.
doi: 10.1007/s00345-025-05758-3.

Cross-talk between Pseudomonas aeruginosa and urinary tract infections

Xiao-Quan Yu  1   2 , Yu-Wen Gong  1   3 , Jun-Qiang Tian  1 , Cheng Peng  1 , Shao-Min Niu  1 , Han-Zhong Feng  4 , Chong-Ge You  5 , Zhi-Ping Wang  6
Affiliations
Review

Cross-talk between Pseudomonas aeruginosa and urinary tract infections

Xiao-Quan Yu et al. World J Urol. .

Abstract

Pseudomonas aeruginosa, a key member of the ESKAPE pathogen group, is a common cause of urinary tract infections (UTIs), particularly in patients with indwelling urinary catheters. Due to its large genome, P. aeruginosa has a high potential for genetic mutations, enabling the development of multidrug resistance. Additionally, it produces a variety of virulence factors, which contribute to persistent and often refractory infections. While UTIs caused by Escherichia coli have been extensively studied, those caused by P. aeruginosa remain less well understood. Understanding the mechanisms underlying the occurrence and progression of P. aeruginosa-associated UTIs, as well as the evolution of its antimicrobial resistance, is crucial for developing more effective treatment strategies. This paper provides an overview of the interaction between P. aeruginosa and UTIs, offering insights that could aid in more effective management and eradication of P. aeruginosa in the urinary tract.

Keywords: Pseudomonas aeruginosa; Anti-biofilm; Antimicrobial resistance; Urinary tract infections; Virulence factors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

References

    1. Stamm WE, Norrby SR (2001) Urinary tract infections: disease panorama and challenges. J Infect Dis 183(Suppl 1):S1–4 - PubMed
    1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269–284 - PubMed - PMC
    1. Lichtenberger P, Hooton TM (2008) Complicated urinary tract infections. Curr Infect Dis Rep 10:499–504 - PubMed
    1. Levison ME, Kaye D (2013) Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr Infect Dis Rep 15:109–115 - PubMed
    1. El Husseini N, Carter JA, Lee VT (2024) Urinary tract infections and catheter-associated urinary tract infections caused by. Microbiol Mol Biol Rev e0006622

MeSH terms

Substances

LinkOut - more resources